Shire Pharmaceuticals ( SHPGY)

Drug/indication: Velaglucerase for Gaucher's disease

Approval decision date: Feb. 28

If approved, "Vela" will trigger a marketing battle in Gaucher's disease against well-entrenched competitor and market leader Cerezyme, owned by Genzyme ( GENZ).

If you liked this article you might like

Ardelyx Has Big Potential

Ardelyx Has Big Potential

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Here's Why XenoPort (XNPT) Stock is Continuing to Surge Today

Trending Tickers: XNPT, OLED, MON, TPUB

Trending Tickers: XNPT, OLED, MON, TPUB